Acorda Therapeutics Inc (ACOR) Analysts See $0.15 EPS

July 26, 2017 - By Marguerite Chambers

 Acorda Therapeutics Inc (ACOR) Analysts See $0.15 EPS
Investors sentiment increased to 0.99 in Q4 2016. Its up 0.10, from 0.89 in 2016Q3. It improved, as 17 investors sold Acorda Therapeutics Inc shares while 56 reduced holdings. 25 funds opened positions while 47 raised stakes. 46.53 million shares or 2.03% less from 47.49 million shares in 2016Q3 were reported.
Louisiana State Employees Retirement holds 0.02% or 18,500 shares. Mason Street Lc holds 0.01% or 10,077 shares. Paloma Prtn Mngmt stated it has 38,784 shares. Pictet Asset Mngmt owns 146,337 shares or 0.01% of their US portfolio. Whittier holds 0.03% or 33,410 shares. United Kingdom-based Blackrock Gru has invested 0% in Acorda Therapeutics Inc (NASDAQ:ACOR). Legal And General Grp Pcl reported 80,038 shares or 0% of all its holdings. Adage Cap Ptnrs Grp Ltd Liability stated it has 800,000 shares or 0.04% of all its holdings. Cap Impact Advsr invested 0.07% in Acorda Therapeutics Inc (NASDAQ:ACOR). Clearbridge Invests Ltd stated it has 0.02% in Acorda Therapeutics Inc (NASDAQ:ACOR). Northwestern Mutual Wealth Mngmt has invested 0% in Acorda Therapeutics Inc (NASDAQ:ACOR). Scout Invests invested in 0.03% or 48,675 shares. Blackrock Institutional Tru Communication Na stated it has 1.25 million shares or 0% of all its holdings. Quantitative Management Limited Liability Corporation has invested 0.02% in Acorda Therapeutics Inc (NASDAQ:ACOR). Cubist Systematic Strategies Limited Liability Corp invested in 9,752 shares.

Since February 9, 2017, it had 1 buying transaction, and 5 sales for $3.94 million activity. The insider LAWRENCE DAVID sold $1.41M. Wasman Jane sold $1.22 million worth of Acorda Therapeutics Inc (NASDAQ:ACOR) on Thursday, February 9. $16,376 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares were sold by Greene Barry E. $1.51 million worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares were sold by Blight Andrew. Shares for $338,998 were bought by COHEN RON on Friday, June 16.

Analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report $0.15 EPS on July, 27 before the open.They anticipate $0.28 EPS change or 215.38 % from last quarter’s $-0.13 EPS. ACOR’s profit would be $7.61M giving it 38.08 P/E if the $0.15 EPS is correct. After having $-0.41 EPS previously, Acorda Therapeutics Inc’s analysts see -136.59 % EPS growth. The stock increased 2.01% or $0.45 during the last trading session, reaching $22.85. About shares traded. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 40.68% since July 26, 2016 and is downtrending. It has underperformed by 57.38% the S&P500.

Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage

Among 9 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Acorda Therapeutics has $65 highest and $21 lowest target. $30.71’s average target is 34.40% above currents $22.85 stock price. Acorda Therapeutics had 17 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was initiated by Aegis Capital on Tuesday, September 1 with “Buy”. The firm has “Buy” rating by Janney Capital given on Monday, March 13. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) earned “Neutral” rating by Goldman Sachs on Wednesday, February 15. TheStreet downgraded the stock to “Buy” rating in Tuesday, August 25 report. The company was initiated on Wednesday, March 30 by Goldman Sachs. The rating was maintained by Cowen & Co with “Buy” on Monday, June 5. The firm has “Outperform” rating by Cowen & Co given on Tuesday, August 25. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) earned “Buy” rating by Aegis Capital on Wednesday, January 6. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) earned “Market Perform” rating by Raymond James on Tuesday, September 1. J.P. Morgan maintained the shares of ACOR in report on Tuesday, June 6 with “Hold” rating.

Acorda Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $1.16 billion. The Firm focuses on developing therapies that restore function and improve the lives of people with neurological disorders. It currently has negative earnings. As of December 31, 2016, the Company marketed three United States Food and Drug Administration -approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

More notable recent Acorda Therapeutics Inc (NASDAQ:ACOR) news were published by: Seekingalpha.com which released: “Acorda’s Pipeline Has Potential” on July 12, 2017, also Reuters.com with their article: “BRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics …” published on July 07, 2017, Streetinsider.com published: “Acorda Therapeutics (ACOR) Submits NDA for INBRIJATM” on June 29, 2017. More interesting news about Acorda Therapeutics Inc (NASDAQ:ACOR) were released by: Fool.com and their article: “Why Acorda Therapeutics Inc Plummeted for a Second Straight Day” published on April 03, 2017 as well as Nasdaq.com‘s news article titled: “Acorda Files NDA for Parkinson’s Disease Candidate Inbrija” with publication date: June 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.